抗 CTLA-4 抗体如何促进癌症免疫？
How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity?
机构信息
Division of Immunotherapy, Institute of Human Virology and Department of Surgery, University of Maryland Baltimore School of Medicine, Baltimore, MD 21201, USA.
出版信息
Trends Immunol. 2018 Dec;39(12):953-956. doi: 10.1016/j.it.2018.10.009.
Abstract
Anti-CTLA-4 antibodies can induce lasting protection for some melanoma patients. However, their therapeutic potential is limited by significant immunotherapy-related adverse effects (irAE). Here, we argue that the therapeutic effect may be based on an agonist activity that is fundamentally distinct, and can be therapeutically differentiated, from the antagonist activity responsible for irAE.
摘要
抗 CTLA-4 抗体可为一些黑色素瘤患者提供持久的保护。然而，其治疗潜力受到显著的免疫治疗相关不良反应 (irAE) 的限制。在这里，我们认为治疗效果可能基于一种激动剂活性，这种活性与导致 irAE 的拮抗剂活性在根本上不同，并且可以进行治疗区分。
相似文献
1
How Does an Anti-CTLA-4 Antibody Promote Cancer Immunity?抗 CTLA-4 抗体如何促进癌症免疫？
Trends Immunol. 2018 Dec;39(12):953-956. doi: 10.1016/j.it.2018.10.009.
2
Preserving the CTLA-4 Checkpoint for Safer and More Effective Cancer Immunotherapy.保留 CTLA-4 检查点以实现更安全、更有效的癌症免疫治疗。
Trends Pharmacol Sci. 2020 Jan;41(1):4-12. doi: 10.1016/j.tips.2019.11.003. Epub 2019 Dec 10.
3
Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.肿瘤和免疫检查点抑制剂相关不良反应的分类特异性模式：系统评价。
Ann Oncol. 2017 Oct 1;28(10):2377-2385. doi: 10.1093/annonc/mdx286.
4
CTLA-4: a moving target in immunotherapy.CTLA-4：免疫疗法中的一个移动靶标。
Blood. 2018 Jan 4;131(1):58-67. doi: 10.1182/blood-2017-06-741033. Epub 2017 Nov 8.
5
Role of the crosstalk between CTLA-4 and NKG2D in the development of anti-CTLA-4 treatment strategies.CTLA-4与NKG2D之间的相互作用在抗CTLA-4治疗策略发展中的作用
Immunotherapy. 2013 Feb;5(2):109-12. doi: 10.2217/imt.12.160.
6
CTLA-4 blockade in tumor models: an overview of preclinical and translational research.肿瘤模型中的CTLA-4阻断：临床前和转化研究综述
Cancer Immun. 2013;13:5. Epub 2013 Jan 22.
7
Breakthrough of the year 2013. Cancer immunotherapy.2013年度重大突破。癌症免疫疗法。
Science. 2013 Dec 20;342(6165):1432-3. doi: 10.1126/science.342.6165.1432.
8
Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors.用于治疗晚期实体瘤的双特异性抗 PD-1/CTLA-4 抗体。
Pharm Pat Anal. 2020 Sep;9(5):149-154. doi: 10.4155/ppa-2020-0017. Epub 2020 Sep 22.
9
Cocktails for cancer with a measure of immunotherapy.含一定量免疫疗法的癌症鸡尾酒疗法。
Nature. 2016 Apr 14;532(7598):162-4. doi: 10.1038/532162a.
10
[Treg cell contribution to anti-CTLA-4 therapeutic effect].[调节性T细胞对抗细胞毒性T淋巴细胞相关抗原4治疗效果的贡献]
Med Sci (Paris). 2020 Jan;36(1):73-76. doi: 10.1051/medsci/2019260. Epub 2020 Feb 4.
引用本文的文献
1
Oncolytic peptide LTX-315 plus an anti-CTLA-4 antibody induces a synergistic anti-cancer immune response in residual tumors after radiofrequency ablation of hepatocellular carcinoma.溶瘤肽LTX-315联合抗CTLA-4抗体在肝细胞癌射频消融后的残留肿瘤中诱导协同抗癌免疫反应。
Cell Death Dis. 2025 Apr 13;16(1):288. doi: 10.1038/s41419-025-07622-z.
2
Exploring Clec9a in dendritic cell-based tumor immunotherapy for molecular insights and therapeutic potentials.探索Clec9a在基于树突状细胞的肿瘤免疫治疗中的分子见解和治疗潜力。
NPJ Vaccines. 2025 Feb 7;10(1):27. doi: 10.1038/s41541-025-01084-2.
3
Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA-4 signaling on CD8 T cells and specifically depleting tumor-resident Tregs.新型 CCR8/CTLA-4 双特异性抗体的临床前开发用于癌症治疗，通过破坏 CD8 T 细胞上的 CTLA-4 信号传导并特异性耗尽肿瘤驻留的 Tregs。
Cancer Immunol Immunother. 2024 Aug 9;73(10):210. doi: 10.1007/s00262-024-03794-3.
4
Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges.非小细胞肺癌中靶向治疗和免疫治疗的耐药机制：克服挑战的有前景策略
Front Immunol. 2024 Apr 9;15:1366260. doi: 10.3389/fimmu.2024.1366260. eCollection 2024.
5
Identification and optimization of peptide inhibitors to block VISTA/PSGL-1 interaction for cancer immunotherapy.鉴定和优化肽抑制剂以阻断VISTA/PSGL-1相互作用用于癌症免疫治疗。
Acta Pharm Sin B. 2023 Nov;13(11):4511-4522. doi: 10.1016/j.apsb.2023.08.003. Epub 2023 Aug 9.
6
Research Progress of Immuno-Inhibitory Receptors in Gynecological Cervical Cancer.妇科宫颈癌免疫抑制受体的研究进展。
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231208846. doi: 10.1177/15330338231208846.
7
Charting new frontiers: Co-inhibitory immune checkpoint proteins in therapeutics, biomarkers, and drug delivery systems in cancer care.开拓新领域：癌症治疗、生物标志物及药物递送系统中的共抑制性免疫检查点蛋白
Transl Oncol. 2023 Dec;38:101794. doi: 10.1016/j.tranon.2023.101794. Epub 2023 Oct 9.
8
Combining energy-based focal ablation and immune checkpoint inhibitors: preclinical research and clinical trials.基于能量的聚焦消融与免疫检查点抑制剂联合应用：临床前研究与临床试验
Front Oncol. 2023 May 1;13:1153066. doi: 10.3389/fonc.2023.1153066. eCollection 2023.
9
Vaccination Following Intratumoral Injection of IL2 and Poly-l-lysine/Iron Oxide/CpG Nanoparticles to a Radiated Tumor Site.于放射治疗后的肿瘤部位瘤内注射 IL2 和多聚赖氨酸/氧化铁/ CpG 纳米粒子后进行接种疫苗。
ACS Nano. 2023 Jun 13;17(11):10236-10251. doi: 10.1021/acsnano.3c00418. Epub 2023 May 22.
10
Antibody-based cancer immunotherapy by targeting regulatory T cells.通过靶向调节性T细胞的基于抗体的癌症免疫疗法。
Front Oncol. 2023 Apr 27;13:1157345. doi: 10.3389/fonc.2023.1157345. eCollection 2023.
本文引用的文献
1
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3 Regulatory T Cells (Tregs) in Human Cancers.抗 CTLA-4 免疫疗法不会耗尽人类癌症中的 FOXP3+调节性 T 细胞（Tregs）。
Clin Cancer Res. 2019 Feb 15;25(4):1233-1238. doi: 10.1158/1078-0432.CCR-18-0762. Epub 2018 Jul 27.
2
Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.APC 上选择性 FcγR 共结合调节靶向 T 细胞抗原的治疗性抗体的活性。
Cancer Cell. 2018 Jun 11;33(6):1033-1047.e5. doi: 10.1016/j.ccell.2018.05.005.
3
A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.重新评估 CTLA-4 检查点阻断在癌症免疫治疗中的作用。
Cell Res. 2018 Apr;28(4):416-432. doi: 10.1038/s41422-018-0011-0. Epub 2018 Feb 22.
4
Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice.在 CTLA4 人源化小鼠中，为了更安全有效地使用抗 CTLA-4 抗体，需要将治疗相关不良反应与免疫治疗相关不良反应区分开来。
Cell Res. 2018 Apr;28(4):433-447. doi: 10.1038/s41422-018-0012-z. Epub 2018 Feb 20.
5
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.纳武利尤单抗与伊匹木单抗联合用药或单药治疗初治黑色素瘤
N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.
6
Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.人类 CTLA4 种系杂合突变个体中的免疫失调。
Science. 2014 Sep 26;345(6204):1623-1627. doi: 10.1126/science.1255904. Epub 2014 Sep 11.
7
Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells.IgG2a 同种型的抗 CTLA-4 抗体通过减少肿瘤内调节性 T 细胞增强抗肿瘤活性。
Cancer Immunol Res. 2013 Jul;1(1):32-42. doi: 10.1158/2326-6066.CIR-13-0013. Epub 2013 Apr 7.
8
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.激活 Fcγ 受体有助于免疫调节受体靶向抗体的抗肿瘤活性。
J Exp Med. 2013 Aug 26;210(9):1685-93. doi: 10.1084/jem.20130573. Epub 2013 Jul 29.
9
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.Fc 依赖性耗竭肿瘤浸润调节性 T 细胞共同定义了抗 CTLA-4 治疗对黑色素瘤的疗效。
J Exp Med. 2013 Aug 26;210(9):1695-710. doi: 10.1084/jem.20130579. Epub 2013 Jul 29.
10
Improved survival with ipilimumab in patients with metastatic melanoma.Ipilimumab 改善转移性黑色素瘤患者的生存。
N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5.
Zotero 插件